These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25098290)

  • 21. Is PD-L1 Expression a Biomarker of Response?
    Colwell J
    Cancer Discov; 2015 Dec; 5(12):1232. PubMed ID: 26516064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospects for targeting PD-1 and PD-L1 in various tumor types.
    Kim JW; Eder JP
    Oncology (Williston Park); 2014 Nov; 28 Suppl 3():15-28. PubMed ID: 25387682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target.
    Bardoli AD; Afshar M; Viney R; Foster M; Porfiri E; Zarkar A; Stevenson R; James ND; Bryan RT; Patel P
    Future Oncol; 2016 Mar; 12(5):595-600. PubMed ID: 26880382
    [No Abstract]   [Full Text] [Related]  

  • 25. Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies.
    Borch TH; Donia M; Andersen MH; Svane IM
    Drug Discov Today; 2015 Sep; 20(9):1127-34. PubMed ID: 26189934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.
    Zhu X; Lang J
    J Gynecol Oncol; 2017 Sep; 28(5):e64. PubMed ID: 28657225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.
    Pal SK; Hu A; Chang M; Figlin RA
    Clin Adv Hematol Oncol; 2014 Feb; 12(2):90-9. PubMed ID: 24892254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?
    Ansell SM
    J Oncol Pract; 2016 Feb; 12(2):101-6. PubMed ID: 26869644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer.
    Peng J; Hamanishi J; Matsumura N; Abiko K; Murat K; Baba T; Yamaguchi K; Horikawa N; Hosoe Y; Murphy SK; Konishi I; Mandai M
    Cancer Res; 2015 Dec; 75(23):5034-45. PubMed ID: 26573793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy.
    Bryan LJ; Gordon LI
    Blood Rev; 2015 Jan; 29(1):25-32. PubMed ID: 25260226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the programmed cell death-1 pathway in breast and ovarian cancer.
    Emens LA; Kok M; Ojalvo LS
    Curr Opin Obstet Gynecol; 2016 Apr; 28(2):142-7. PubMed ID: 26881392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting immune checkpoints in lymphoma.
    Ansell SM
    Curr Opin Hematol; 2015 Jul; 22(4):337-42. PubMed ID: 26049755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Targeting the PD-1/PD-L1 immune checkpoint signal - a new treatment strategy for cancer].
    Hamanishi J; Konishi I
    Gan To Kagaku Ryoho; 2014 Sep; 41(9):1071-6. PubMed ID: 25248890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions.
    Karim S; Leighl N
    Future Oncol; 2016 Jan; 12(1):9-23. PubMed ID: 26631501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Releasing the Brake on the Immune System: The PD-1 Strategy for Hematologic Malignancies.
    Bryan LJ; Gordon LI
    Oncology (Williston Park); 2015 Jun; 29(6):431-9. PubMed ID: 26091677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
    Weber J
    Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. B7-H1/PD-1 blockade therapy in urological malignancies: current status and future prospects.
    Yu L; Wang Y; Shao S; Yang M; Niu H; Yu Q; Wang X
    Tumori; 2015; 101(5):549-54. PubMed ID: 26045125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 Inhibitors.
    Poulet FM; Wolf JJ; Herzyk DJ; DeGeorge JJ
    Birth Defects Res B Dev Reprod Toxicol; 2016 Apr; 107(2):108-19. PubMed ID: 27062127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2015 Jan; 51(1):7-20. PubMed ID: 25685857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.